Lesley Jenkins had surgery to remove a tumour that was discovered following a routine bowel test.

Cancer researchers are one step closer to developing an effective vaccine to treat people with clear cell renal cell carcinoma (ccRCC), the most common type of kidney cancer among adults. In an early-stage clinical trial led by the Dana-Farber Cancer Institute in Boston,

A new vaccine for kidney cancer shows excellent preliminary results. All patients on the trial had no evidence of cancer three years after the pioneering treatment.

In a Phase 1 study, nine people with advanced kidney cancer became cancer free after receiving personalized vaccines.

Patients with advanced kidney cancer who received an experimental vaccine after their tumors were removed were still cancer-free years later in a small early-stage trial, researchers reported in Nature.

Doctors at Dana-Farber say this personalized vaccine can be given after surgery to remove a tumor and train the body’s immune system to eliminate tumor cells.